Breast Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Trastuzumab for Women with HER2-Low Breast Cancer
(Posted: 06/26/2012) - In this clinical trial, women who have recently undergone surgical resection for HER2-low breast cancer and are at high risk for recurrence will undergo adjuvant chemotherapy and be randomly assigned to 1 year of trastuzumab treatment or no trastuzumab.
- Surgical Removal of Primary Tumor for Metastatic Breast Cancer
(Posted: 02/21/2012) - In this clinical trial, women with newly diagnosed metastatic breast cancer who are undergoing systemic therapy and whose disease does not progress within 16 weeks of starting that therapy will be randomly assigned to continue systemic therapy or to undergo surgical resection of their primary tumor.
- Making Decisions about Cancer Prevention Medications for Breast Cancer
(Posted: 01/10/2012) - In this study, women age 35 or older who discuss the use of drugs called SERMs for breast cancer prevention with a health care provider will be asked to complete a questionnaire about their discussion and whether they have come to a decision about using a SERM for risk reduction, as well as a second questionnaire about their decision-making process.
- Sequencing Treatment with a PARP Inhibitor and Chemotherapy
(Posted: 09/06/2011) - In this clinical trial, patients will be treated in 21-day cycles, with the first cycle being either intravenous carboplatin on day 1 followed by 7 days of oral olaparib or oral olaparib for 7 days followed by intravenous carboplatin on day 8. In the second cycle, the treatment assignments will be reversed.
- Metformin to Treat Early-Stage Breast Cancer
(Posted: 05/31/2011) - In this trial, nondiabetic women or men younger than age 75 who have been diagnosed with early-stage breast cancer within the previous 12 months and who have undergone surgery to remove their tumor will be randomly assigned to take metformin or placebo pills twice a day for 5 years.